DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)

Phase 4

Completed

Conditions: Chronic Angina

First Posted Date: 2008-03-26

Last Posted Date: 2012-07-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 172

Registration Number: NCT00644332

Locations: 🇺🇸
Total Heart Care, PC, New York, New York, United States
🇺🇸
South Denver Cardiology Associates, PC, Littleton, Colorado, United States
🇺🇸
Jacksonville Center for Clinical Research, Jacksonville, Florida, United States

and more 24 locations

Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: EFV+TDF
Drug: EFV+3TC+TDF

First Posted Date: 2008-03-26

Last Posted Date: 2008-06-30

Lead Sponsor: Gilead Sciences

Target Recruit Count: 140

Registration Number: NCT00643968

Locations: 🇫🇷
France and French West Indies, Paris, France

An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Emtricitabine

First Posted Date: 2008-03-25

Last Posted Date: 2008-04-10

Lead Sponsor: Gilead Sciences

Target Recruit Count: 16

Registration Number: NCT00642291

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

Phase 4

Completed

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Placebo
Drug: Ambrisentan
Drug: Sildenafil
Drug: Tadalafil

First Posted Date: 2008-02-18

Last Posted Date: 2012-07-30

Lead Sponsor: Gilead Sciences

Target Recruit Count: 38

Registration Number: NCT00617305

Locations: 🇺🇸
Scott & White Memorial Hospital, Temple, Texas, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 27 locations

ONCE - Only Nocturnal Combination Evaluation of Antiretroviral-Experienced HIV 1 Infected Subjects Switching to Atripla

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg

First Posted Date: 2008-02-14

Last Posted Date: 2011-11-21

Lead Sponsor: Gilead Sciences

Target Recruit Count: 115

Registration Number: NCT00615745

Locations: 🇬🇧
Gilead Sciences, Cambridge, United Kingdom

ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Kivexa plus Sustiva
Drug: Atripla

First Posted Date: 2008-02-14

Last Posted Date: 2010-08-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 159

Registration Number: NCT00615810

Locations: 🇬🇧
Gilead Sciences, Granta Park, Cambridge, Abington, United Kingdom

Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Biological: IMMU-107 (hPAM4)

First Posted Date: 2008-01-29

Last Posted Date: 2021-08-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 80

Registration Number: NCT00603863

Locations: 🇺🇸
Christiana Care Health Services, Newark, Delaware, United States
🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States

and more 8 locations

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

Phase 1

Completed

Conditions: Chronic Lymphocytic Lymphoma

Interventions: Biological: milatuzumab

First Posted Date: 2008-01-29

Last Posted Date: 2021-08-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 19

Registration Number: NCT00603668

Locations: 🇺🇸
M. D. Anderson Cancer Center, Orlando, Florida, United States
🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

and more 2 locations

Safety and Efficacy Study of 90Y-hPAM4 at Different Doses

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Biological: 90Y-hPAM4

First Posted Date: 2008-01-17

Last Posted Date: 2021-08-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 21

Registration Number: NCT00597129

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Goshen Cancer Center, Goshen, Indiana, United States
🇺🇸
University of Medicine and Dentistry, Newark, New Jersey, United States

and more 1 locations

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma
Lymphoma, Diffuse
Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic

First Posted Date: 2008-01-17

Last Posted Date: 2021-08-18

Lead Sponsor: Gilead Sciences

Target Recruit Count: 39

Registration Number: NCT00596804

Locations: 🇬🇧
University of Leicester, Leicester, United Kingdom
🇫🇷
Centre hospitalier Lyon, Lyon, Pierre Benite Cedex, France
🇫🇷
Service Des Maladies Du Sang, Lille, Cedex, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy